A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Catalyst OrthoScience introduces the Archer™ R1 Reverse Shoulder System: Rebrands its Archer™ CSR Total Shoulder System

Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, is introducing its new Archer™ R1 Reverse Shoulder System as its Archer™ CSR Total Shoulder System continues to gain market share.

“Since we introduced our first product in 2016, Catalyst has remained targeted on the shoulder arthroplasty space,” said Brian K. Hutchison, chairman and CEO of Catalyst OrthoScience. “We are building out a comprehensive, novel portfolio focused precisely on that market. The tenets of our product portfolio are centered around precise, targeted placement of bone-sparing implants. Our next generation implant design, paired with unique, patented instrumentation and streamlined surgical techniques, allows for surgeon-targeted implant positioning. We feel the Archer product family name represents these tenets well in the market place.”

Recently, Catalyst OrthoScience announced 510(k) clearance of the Archer R1 Reverse Shoulder System, expanding its product portfolio with multiple arthroplasty options. Catalyst’s reverse shoulder system is a single-tray arthroplasty system that was engineered to combine the most beneficial and evidence-based attributes of reverse shoulder arthroplasty design. The system offers surgeon-targeted implant positioning, a streamlined and versatile system, and bone sparing implants. Catalyst is starting a limited user release in the United States this quarter followed by a commercial launch later in 2021.

As part of this important milestone, the company is rebranding its flagship stemless, ellipsoid anatomic system to the Archer CSR Total Shoulder System. Since its introduction in 2016, Catalyst’s Archer CSR system has experienced explosive adoption and growth. The Archer CSR system is unique, offering precision and accuracy in shoulder restoration while preserving the patient’s bone and soft tissue. It is a single-tray, bone-preserving total shoulder arthroplasty system containing a precision elliptical humeral head and less invasive glenoid component, using patented instrumentation designed for consistent anatomic joint line restoration and glenoid insertion.

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy